Metabolic Syndrome

Definition

Metabolic syndrome (MetS) is a clinical condition defined by the simultaneous occurrence of ≥3 of the following five components: (1) central/abdominal obesity, (2) dyslipidaemia (elevated triglycerides), (3) impaired glucose metabolism/insulin resistance, (4) elevated blood pressure, and (5) low HDL-cholesterol. This harmonised definition reflects consensus from the International Diabetes Federation, American Heart Association, and National Heart, Lung and Blood Institute.

Key Concepts

Epidemiology

• Prevalence in developed countries: 20–25% of adult population; Spain ~22.7%; incidence increases with age sources/diet-mets-nutrients-2020 (high)
• MetS is a public health priority due to its strong association with T2DM (2-fold risk increase) and major cardiovascular events (5-fold risk increase) sources/diet-mets-nutrients-2020 (high)
• Additional comorbidities linked to MetS: cancer, neurodegenerative disease, NAFLD, reproductive disorders, lipid and circulatory disorders, atherosclerosis, and all-cause mortality sources/diet-mets-nutrients-2020 (high)

Pathophysiology and Risk Factors

• Central obesity and insulin resistance are the core drivers; abdominal fat excess promotes chronic low-grade inflammation, dyslipidaemia, and impaired glucose metabolism
• Modifiable lifestyle factors — particularly dietary habits and physical inactivity — are the primary determinants of MetS incidence and progression
• Pro-inflammatory state characteristic of MetS; inflammatory biomarkers (hsCRP, IL-6, TNF-α) elevated and partially reduced by weight loss and diet quality

Dietary Management: Comparative Evidence

Mediterranean Diet (Best Overall Evidence)

• Meta-analysis (12 cross-sectional/prospective cohorts): higher MedDiet adherence → 19% lower MetS risk (RR 0.81; 95% CI 0.71–0.92); waist circumference RR 0.82; BP RR 0.87 sources/diet-mets-nutrients-2020 (high)
• CARDIA study (n=4,713): HR 0.67 (95% CI 0.49–0.90) for MetS development with high MedDiet adherence sources/diet-mets-nutrients-2020 (high)
• SU.VI.MAX study (n=3,232, 6-year follow-up): 53% lower MetS risk in highest MedDiet tertile sources/diet-mets-nutrients-2020 (high)
• MedDiet components: 35–45% kcal from fat (primarily MUFA/PUFA from EVOO and nuts); 15% protein; 40–45% CH; EVOO polyphenols provide anti-inflammatory and antioxidant effects; oleic acid improves insulin resistance and lipid profile
• Considered the first-line dietary strategy for MetS prevention and management sources/diet-mets-nutrients-2020 (high)

DASH Diet (Strong Evidence for Blood Pressure and MetS Risk)

• Meta-analysis (30 RCTs, n=5,545): DASH → SBP −3.2 mmHg, DBP −2.5 mmHg vs control; ranked most effective in network meta-analysis vs 13 patterns (indirect comparison only) sources/diet-mets-nutrients-2020 (high)
• Cross-sectional study (n=1,493): high DASH adherence → 48% less MetS risk; lower BMI, waist circumference, and inflammatory markers sources/diet-mets-nutrients-2020 (high)
• Paediatric cohort (n=425, age 6–18): 64% lower MetS risk with high DASH adherence sources/diet-mets-nutrients-2020 (high)
• DASH dietary quality driven by high fiber (>30 g/d), potassium, magnesium, calcium; low SFA and sodium sources/diet-mets-nutrients-2020 (high)
• Head-to-head vs MedDiet (Filippou 2023 RCT, n=240): DASH = MedDiet on 24h ambulatory BP (gold standard); MedDiet marginally superior for office SBP only (−3.2 mmHg, P<0.001); both significantly outperform salt restriction alone sources/dash-meddiet-cn-2023 (high)

Plant-Based Diets

• Vegetarian diet (7 RCTs): SBP −4.8 mmHg, DBP −2.2 mmHg vs omnivorous; weight loss −2.88 kg (11 RCTs) sources/diet-mets-nutrients-2020 (high)
• Substitution of red meat with plant-based protein → reduced total cholesterol and LDL-c (meta-analysis 36 RCTs) sources/diet-mets-nutrients-2020 (high)
• Healthy plant-based patterns reduce MetS risk; unhealthy plant-based diets (refined grains, SSBs, pastries) do not sources/diet-mets-nutrients-2020 (high)

Low-Carbohydrate and Ketogenic Diets

• High CH intake: 2.5% increase in MetS risk per 5% energy from CH (meta-analysis 18 studies, n=69,554) sources/diet-mets-nutrients-2020 (high)
• Low-CH diet (<40% kcal) vs low-fat without energy restriction: greater weight loss −3.5 kg, improved TG, HDL-c, and TC:HDL ratio at 1 year (Bazzano RCT) sources/diet-mets-nutrients-2020 (high)
• Ketogenic diet vs low-fat (Bueno meta-analysis): weight loss −0.91 kg greater, TG −0.18 mmol/L, DBP −1.43 mmHg, HDL-c +0.09 mmol/L sources/diet-mets-nutrients-2020 (high)
• PURE cohort (n=135,335): U-shaped CH-mortality curve; optimal intake 50–55% kcal from CH; both very high (>70%) and very low (<40%) CH associated with increased mortality sources/diet-mets-nutrients-2020 (high)
• Very-low-CH diets eliminate healthy foods (vegetables, fruits, whole grains) associated with chronic disease prevention; concern for long-term safety sources/diet-mets-nutrients-2020 (high)

Low-Fat Diet

• Meta-analysis (34 RCTs): 18% lower all-cause mortality in obese adults with weight-loss low-fat interventions sources/diet-mets-nutrients-2020 (high)
• Conflicting results in MetS specifically; no consistent effect on CVD/CHD in postmenopausal women; no lower MetS prevalence in older high-CVD-risk subjects sources/diet-mets-nutrients-2020 (high)
• DIETFITS trial: low-fat and low-CH produce equal weight loss — no difference between groups sources/diet-mets-nutrients-2020 (high)
• Short-term BP/lipid benefits but inferior to MedDiet and DASH in long-term BP management sources/diet-mets-nutrients-2020 (high)

High-Protein Diet

• Greatest consistent benefit: triglyceride reduction sources/diet-mets-nutrients-2020 (high)
• RCT (n=118 MetS): hypocaloric high-protein → greater weight loss (−7.0 vs −5.1 kg); no between-group difference in MetS criteria sources/diet-mets-nutrients-2020 (high)
• Unsaturated fat replacement of CH (not high-protein itself) improves insulin sensitivity (OmniHeart study) sources/diet-mets-nutrients-2020 (high)

Intermittent Fasting

• Cardiometabolic benefits: weight loss, improved insulin resistance, dyslipidaemia, and BP reduction; decreased T2DM and CVD risk sources/diet-mets-nutrients-2020 (high)
• Complex applicability — requires supervised healthcare professional guidance to avoid adverse effects

General Principles

• Overall dietary quality > macronutrient distribution for MetS management sources/diet-mets-nutrients-2020 (high)
• Dietary advice must focus on the overall dietary pattern, not isolated nutrient restriction sources/diet-mets-nutrients-2020 (high)
• Adherence to the dietary intervention is the single most decisive factor in achieving beneficial MetS outcomes, regardless of dietary pattern chosen sources/diet-mets-nutrients-2020 (high)
• Energy-restricted dietary patterns + increased physical activity remain essential components of MetS treatment sources/diet-mets-nutrients-2020 (high)
• Effectiveness of dietary intervention is conditioned by the patient's prior metabolic state (presence of insulin resistance, T2DM, altered fasting glucose) sources/diet-mets-nutrients-2020 (high)

Contradictions / Open Questions

• DASH vs. MedDiet for BP — indirect vs. direct evidence: Network meta-analyses ranked DASH superior to MedDiet for BP. The first head-to-head RCT (Filippou 2023, n=240, 3 months, salt restriction background) shows MedDiet = DASH on 24h ambulatory BP (gold standard) and MedDiet > DASH for office SBP only. Both outperform salt restriction alone. The office SBP advantage of MedDiet may partly reflect white-coat attenuation. Clinically, the two diets are equivalent for BP management when combined with sodium restriction. sources/dash-meddiet-cn-2023 (high), sources/diet-mets-nutrients-2020 (high)
• MedDiet vs. DASH superiority (MetS framework): Castro-Barquero 2020 concludes MedDiet is the "new paradigm" for MetS treatment; the AHA 2026 heart-healthy statement rates MedDiet, DASH, pescatarian, and vegetarian as equivalent without designating one as superior. The direct BP RCT supports this equivalence framing. sources/diet-mets-nutrients-2020 (high), sources/diet-aha-2026 (very high), sources/dash-meddiet-cn-2023 (high)
• Short-term Paleolithic/Atkins vs. DASH for BP: Ge et al. (cited within this review) identified Paleolithic and Atkins diets as most effective for BP management at 6 months, but not at 1 year — this transient advantage is not reflected in summary statements recommending DASH as definitively superior sources/diet-mets-nutrients-2020 (high)
• Low-fat diet in MetS: Conflicting results across trials; the DIETFITS trial shows equal weight loss with low-fat and low-CH approaches, while other RCTs show superiority of low-CH for glycemic and lipid parameters in T2DM — inconsistency in the evidence base sources/diet-mets-nutrients-2020 (high)
• Ketogenic diet: metabolic benefits vs. long-term CV safety: Short-term metabolic improvements well-documented, but elimination of vegetables/fruits/whole grains raises concern, and the AHA 2026 statement notes case series reports of dramatic LDL-C elevation with ketogenic diets — long-term cardiovascular safety remains unresolved sources/diet-mets-nutrients-2020 (high), sources/diet-aha-2026 (very high)
• U-shaped CH-mortality curve vs. low-CH advocacy: PURE and Seidelmann data show optimal mortality at 50–55% CH intake (not low-CH), yet low-CH diets are advocated for short-term MetS components — the long-term relevance of macronutrient targets for metabolic vs. mortality outcomes diverges sources/diet-mets-nutrients-2020 (high)

Connections

• Related to concepts/Heart-Healthy-Dietary-Patterns — MetS as the primary therapeutic target for dietary interventions
• Related to concepts/Blood-Pressure-Target-T2DM — BP management and insulin resistance as MetS criteria
• Related to concepts/Hypertension-HMOD — elevated BP as a MetS component and HMOD driver
• Related to concepts/Iron-Deficiency-in-HF — NAFLD and cardiometabolic comorbidity overlap
• Related to entities/Hypertension — BP as MetS criterion; DASH diet evidence

Sources

• sources/diet-mets-nutrients-2020
• sources/dash-meddiet-cn-2023